AC Immune SA (ACIU) has released an update.
AC Immune SA reports a significant turnaround in its third-quarter 2024 financial results, achieving a net income of CHF 5.5 million compared to a loss in the previous year. This improvement is largely driven by contract revenues of CHF 25.5 million, marking a notable contrast from the absence of revenue in 2023. However, the company’s shareholders’ equity has decreased from CHF 160.6 million to CHF 130.2 million over the same period.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
